Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2367 - ATM as a DNA Damage Response Protein in Uveal Melanoma: Association with Clinicopathological Factors and Prognostic Outcome

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Jayanti Jha

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

J. Jha1, M.K. Singh2, N. Pushker1, S. Sen2, S. Kashyap2

Author affiliations

  • 1 Ophthalmology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2 Ocular Pathology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
More

Resources

Abstract 2367

Background

Uveal melanoma (UM) is an intraocular malignancy commonly arising from choroid which can cause visual loss or metastasis. Till date, there is no current study available on UM with respect to ATM (Ataxia Telangiectasia Mutated) protein that induces DNA damage response. Several studies revealed that loss of nuclear ATM (nATM) in various cancers like pancreatic, colorectal, gastric cancer leads to poor prognosis. This signifies ATM protein as a prognostic biomarker for cancer progression. Therefore, the aim of the study is to detect the expression/localization of ATM protein in uveal melanoma patients.

Methods

Expression of nATM was investigated on 69 formalin fixed paraffin embedded choroidal melanoma samples by immunohistochemistry and validated by western blotting. Results were then correlated with clinical and histopathological parameters. To determine the prognostic significance, Kaplan–Meier analysis and multivariate analysis by Cox’s Proportional Hazards Model was performed.

Results

There was a male preponderance in our study. Histopathological high-risk factors were identified in 30/69 (43.5%) cases. Loss of nATM was found in 65.2% of the cases. Loss of nATM was statistically significant with epithelioid cell type, high pigmentation, LTD >10mm, HRFs>1, tumour height and advanced tumour staging (p < 0.05). On multivariate analysis, advanced tumour staging found out to be an independent prognostic factor.

Conclusions

Our data suggest that loss of nATM protein might serve as a potential prognostic marker in the pathogenesis of uveal melanoma and leads to increased risk of metastasis. These findings demonstrate an important role of ATM protein and may have a therapeutic potential in uveal melanoma. However, further studies are required in a larger cohort of patients with longer follow up and translational validation needs to be performed.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings